Aflibercept
- Generic Name
- Aflibercept
- Brand Names
- Eylea, Zaltrap, Yesafili
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 862111-32-8
- Unique Ingredient Identifier
- 15C2VL427D
- Background
Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa). It contains approximately 15%...
- Indication
The opthalmic agent is used for the treatment of neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and retinopathy of prematurity (ROP).
...
- Associated Conditions
- Branch Retinal Vein Occlusion With Macular Edema, Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Macular Edema With Central Retinal Vein Occlusions, Metastatic Colorectal Cancer (CRC), Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD), Retinopathy of Prematurity (ROP)
- Associated Therapies
- -
Aflibercept for Diabetic Macular Edema In Real-life Practice in GREece
- Conditions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- University of Athens
- Target Recruit Count
- 100
- Registration Number
- NCT05683912
- Locations
- 🇬🇷
University of Athens, Athens, Greece
A Study of Longer Interval of IVT IBI302 in Subjects With nAMD
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 132
- Registration Number
- NCT05403749
- Locations
- 🇨🇳
Shanghai First People's Hospital, Shanghai, Shanghai, China
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
- First Posted Date
- 2022-04-25
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 366
- Registration Number
- NCT05345236
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 346
- Registration Number
- NCT05324774
- Locations
- 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China
Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2022-04-12
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05324592
- Locations
- 🇨🇳
Beijing tongren hospital affliated to capital medical university, Beijing, Beijing, China
Ranibizumab Versus Aflibercept for CRVO in Young Patients.
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- South Valley University
- Target Recruit Count
- 40
- Registration Number
- NCT05282420
- Locations
- 🇪🇬
Ahmed Ali Ahmed Amer, Qinā, Qena, Egypt
Anti-VEGF in Real-world
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Wenbin Wei
- Target Recruit Count
- 1000
- Registration Number
- NCT05222633
- Locations
- 🇨🇳
Wen-Bin Wei, Beijing, Beijing, China
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
- Conditions
- Interventions
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 140
- Registration Number
- NCT05178745
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05126966
- Locations
- 🇭🇰
Hong Kong Eye Hospital; CUHK Eye Centre, Mongkok, Hong Kong
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇩🇰Sjællands Universitetshospital, Roskilde; Øjenafdelingen, Roskilde, Denmark
A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
- First Posted Date
- 2021-10-01
- Last Posted Date
- 2023-08-18
- Lead Sponsor
- Oxurion
- Target Recruit Count
- 16
- Registration Number
- NCT05063734
- Locations
- 🇱🇻
Pauls Stradins Clinical University Hospital, Riga, Latvia
🇺🇸Salehi Retina Institute Inc., Huntington Beach, California, United States
🇺🇸Retina Center of Texas, Southlake, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.